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ABSTRACT
Background: Human immunodeficiency virus (HIV)-associated nephropathy typically leads to end-
stage renal disease requiring dialysis within 3-4 months. This report describes the prenatal course
of a patient with HIV-associated nephropathy requiring dialysis during pregnancy.
Case: A 23-year-old nulliparous, black female presented at 13 weeks gestation with a history of
HIV-associated nephropathy and anemia. She had a CD4 count of350/mm3, a total urinary protein
of 1.7 g/day, and a serum creatiriine of 4.8 mg/dl. The patient was begun on zidovudine, 500
mg daily, and erythropoietin, 4,000 units weekly. At 23 weeks gestation, when she developed
hypertension, a total urinary protein of 3.4 g/day, and a serum creatinine of 4.4 mg/dl, she was
hospitalized. Her renal function continued to deteriorate, requiring hemodialysis. At 29-4/7 weeks,
she developed preterm labor, for which she was placed on indomethacin. Four days later, at 30
weeks gestation, she delivered a viable male infant.
Conclusion: HIV-associated nephropathy during pregnancy can be successfully managed with
hemodialysis. (C) 1996 Wiley-Liss, Inc.
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he incidence ofhuman immunodeficiency virus
(HIV) is rising rapidly among women of repro-
ductive age, particularly among black women. Non-
infectious complications of HIV, such as nephropa-
thy, can occur. In most cases, this entity rapidly
progresses to end-stage renal disease requiring dial-
ysis within 3-4 months. Renal failure during preg-
nancy, a difficult problem to manage, can result in
an increased risk of perinatal loss. This report of
HIV-associated nephropathy during pregnancy il-
lustrates the therapeutic issues related to this com-
plication.
CASE REPORT
A 23-year-old black woman, G,P0, presented for
prenatal care at 13 weeks gestation to the Infectious
Disease Clinic at Lyndon Baines Johnson Hospital.
The patient, who had been HIV positive for 1 year,
denied any history of IV drug abuse.
One year earlier, she had been hospitalized with
pyelonephritis, generalized lymphadenopathy, and
nephrotic syndrome. An axillary lymph node was
suspicious for lymphoma and a biopsy was read as
reactive follicular hyperplasia consistent with HIV
lymphadenopathy. A computed axial tomogram re-
vealed retroperitoneal lymphadenopathy, and a re-
nal sonogram showed bilateral echogenic kidneys.
A kidney biopsy (prior to pregnancy) showed focal
segmental glomerulosclerosis. Immunofluores-
cence studies demonstrated C3 and IgM staining
of the sclerotic glomeruli.
Immunofluorescence studies were negative for
IgA deposits. The biopsy results were consistent
with HIV-associated nephropathy. A Western blot
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confirmed an HIV infection. The patient’s CD4
count was 471/mm at the time of her initial diagno-
sis. She had a blood urea nitrogen (BUN) of 44
mg/dl, a serum creatinine of 5.5 mg/dl, and a total
urinary protein of 4 g/day. Because she was not
expected to survive long with end-stage renal dis-
ease, her nephrologist elected not to start antiret-
roviral therapy with zidovudine. A right-wrist arte-
rial venous fistula was created 4 months later in
anticipation of dialysis. The patient was subse-
quently lost to follow-up for approximately 6
months.
At her initial prenatal visit, her blood pressure
was 117/60. She had a hemoglobin of 9.8 mg/dl and
hematocrit of 27.7%. Her CD4 count was 380 mm
and serum creatinine was 4.8 mg/dl, with a BUN
of 52 mg/dl. The total urinary protein was 1.7
g/day and serum albumin was 2.7 mg/dl. She was
begun on multivitamins; ferrous sulfate; recombi-
nant erythropoietin, 4,000 units weekly; and zido-
vudine, 500 mg daily. The nephrology service was
consulted, and her renal function was serially as-
sessed by evaluations of serum creatinine and BUN
and 24-h urine collections for total protein and creat-
inine clearance. Ultrasounds at 10 and 20 weeks
gestation were consistent with her menstrual dates,
and no fetal anomalies were noted.
Her prenatal course was uncomplicated until 23
weeks gestation when her blood pressure increased
to 143/92. She had a total protein of 3.4 g/day and
creatinine clearance of 15 ml/min. Her serum creati-
nine was 4.4 mg/dl. Her anemia was slightly worse,
with a hemoglobin of 8.3 mg/dl and hematocrit of
22.8%. The clinical picture was suspicious for either
worsening renal disease or mild superimposed pre-
eclampsia. After she was hospitalized, her blood
pressure improved slightly at bed rest. However,
her renal function continued to deteriorate over the
ensuing 8 days. Worsening azotemia and increasing
serum creatinine of5.8 mg/dl were noted and hemo-
dialysis was begun. She tolerated hemodialysis well,
with minimal maternal hypotension and rare fetal
heart-rate decelerations. Dialysis was performed 3
times per week to maintain a predialysis BUN of
<50 mg/dl. The patient was discharged from the
hospital at 26 weeks gestation and closely followed
as an outpatient.
At 29-6/7 weeks, the patient complained of vagi-
nal bleeding. An examination revealed the cervix
to be 3 cm dilated and cm long, with regular
uterine contractions every 5 min. Successful toco-
lysis was achieved with indomethacin, and beta-
methasone was administered to enhance the fetal
lung maturity. Four days later, labor ensued, and
she received intrapartum IV zidovudine. A viable
male infant was spontaneously delivered at 30
weeks gestation. The infant weighed 1,360 g, with
Apgars of 8 at and 5 min.
Her postpartum course was unremarkable. Her
blood pressure returned to baseline at her postpar-
tum visit. For 24 months, she has been maintained
on hemodialysis, 3 times per week, and zidovudine,
500 mg day, with no opportunistic infections to date.
Her infant is HIV seronegative at 2 years of age.
DISCUSSION
HIV-associated nephropathy was first reported in
1983. A patient with this complication typically
presents with proteinuria (>3.5 g/day) and hypoal-
buminemia. More than 95% of all cases of HIV-
associated nephropathy are found in blacks, with a
male-to-female ratio of 10:1.1 Approximately 50% of
patients with HIV-associated nephropathy acquired
HIV infection through IV-drug abuse, while the
remaining cases acquired it through sexual contact.
The predominant pathologic lesion in HIV-asso-
ciated nephropathy is focal segmental glomerulo-
sclerosis, which accounts for over 90% of the histo-
logic changes. The characteristic features of HIV-
associated focal segmental glomerulosclerosis are
qualitatively similar to other forms of focal segmen-
tal glomerulosclerosis, including cases attributable
to drug abuse and idiopathic cases.
While the time required for the development of
nephropathy in adults is not known and the initial
time of the acquisition of HIV infection is difficult
to determine, the onset of proteinuria in children
ranges from 2.5 to 4.9 years. HIV-associated ne-
phropathy results in a rapid loss of renal function
that leads to end-stage renal disease, typically
within 4 months, although wide variations in the
time course are seen. Once dialysis becomes neces-
sary, the survival is generally <6 months. Recent
data indicate that the clinical stage ofHIV infection
may be the most important determinant of survival.
Ortiz et al. found the mean duration of dialysis to
range from 74 days in acquired immunodeficicncy
syndrome (AIDS) patients to 255 days in asymp-
tomatic patients. These data suggest that mainte-
nance dialysis should be performed only in cases
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ofasymptomatic HIV infection. In 1993, the diagno-
sis of AIDS was assigned to anyone with a CD4
count of <200 min3; therefore, asymptomatic AIDS
patients should also be considered for mainte-
nance hemodialysis.
End-stage renal disease during pregnancy is as-
sociated with a poor perinatal outcome, particularly
for a patient with primary glomerulonephritis. Focal
segmental glomerulosclerosis has a higher rate of
perinatal loss (23%) and preterm labor (32%) than
other types of glomerulonephritis, presumably be-
cause of the greater prevalence of renal insuffi-
ciency. A review of 24 pregnant patients undergo-
ing dialysis after 1990 showed that 52% of the
pregnancies resulted in surviving infants. Addition-
ally, 79% of these women delivered after 28 weeks
gestation, although only infant was delivered at
term.
In cases ofpreterm labor, indomethacin has been
used. It appears to be well tolerated for short courses
of therapy. Recombinant erythropoietin in preg-
nancy is also well tolerated. 6’7 Although it has not
received U.S. Food and Drug Administration ap-
proval for use during pregnancy, theoretically, it
should not cross the placenta since it has a molecular
weight of 30,400 daltons. In a small series of preg-
nant women on dialysis, the response to erythropoi-
etin was diminished. Iron-deficiency anemia is the
most common reason for resistance to erythropoie-
tin, indicating the advantage of placing pregnant
women with end-stage renal disease on iron therapy
early. Our patient, who responded well to erythro-
poietin, did not require any increase in dosage dur-
ing the pregnancy.
Our patient was offered the AIDS Clinical Trial
Group 076 regimen because of the beneficial de-
crease in maternal-fetal transmission of HIV infec-
tion. A full dose of zidovudine (500 mg/day) was
given, as very little is excreted renally. Of note,
uncontrolled observations suggest that zidovudine
can retard or attenuate progression to end-stage re-
nal disease and that discontinuation of zidovudine
can lead to a more fulminant clinical course.
A pregnancy complicated by HIV-associated ne-
phropathy requiring dialysis can result in a viable
infant despite the increased risk of preterm deliv-
ery, as our case demonstrates. Recombinant erythro-
poietin and zidovudine, both ofwhich are well toler-
ated, should be considered in the management of
such a patient.
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